Omnicell, Inc. (OMCL) has experienced substantial growth, with shares increasing by 57.3% over the past year, significantly outperforming the healthcare industry, which fell by 30.3%, and the S&P 500’s 33% gain. The company, headquartered in Mountain View, California, specializes in medication-use automation solutions, enhancing patient safety and operational efficiency.
For 2026, Omnicell anticipates revenues of $1.24 billion, reflecting a 4.9% growth, with earnings per share projected to rise 21.6% to $1.97. The Zacks Consensus Estimate for 2027 earnings is $2.23, marking a 13.2% increase. Despite facing challenges such as labor shortages and escalating inflation costs, the company’s liquidity remains strong, with $239.2 million in cash and cash equivalents against $168 million in total debt.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
